CEO Comments

TRANSFORMATIVE ACQUISITION TAKES THE GROUP TO A NEW LEVEL Nanologica has a positive development on a growing market with strong macro factors. With a now stabilized production, the company is well positioned to deliver sustainable growth in our chromatography business. We have also made a strategic acquisition that strengthens our capacity and expertise in production, and which is expected to contribute positively to the Group’s earnings and cash flow as early as 2026. At Group

With stable production and a first order on the insulin market, the company is advancing its positions, although this did not translate into significantly higher sales during the past quarter. Stable production gives us a more secure delivery capacity and thereby the conditions to create stronger customer relationships. This is beginning to be reflected in the order intake for the fourth quarter, which already amounts to approximately SEK 5.7 million.   After several delays it

As expected, the second quarter was not as strong in terms of sales as the first. However, we are making clear progress in our work to streamline the production process, which will generate positive effects over time. We also received our first order from the US for testing NLAB Saga® on a production scale. The company’s top priority continues to be the production of NLAB Saga®. During the quarter, we have introduced techniques to increase

SALES RECORD FOR A SINGLE QUARTER The first quarter of the year meant a sales record for a single quarter for the company and a good start to the new year. The ongoing positive customer dialogues combined with a continued stabilization of the production process create good conditions for increased sales growth during the year. Net sales for the quarter amounted to SEK 10,751 thousand and consist mainly of sales of our silica media NLAB

After many years of working with various technologies and products, Nanologica has developed into a pure chromatography company with products for purification of pharmaceuticals during production, on a global market. Today we provide pharmaceutical manufacturers with products that needed to manufacture  fast-growing GLP-1 analogues and insulin. With these products and our expertise in method and application development, we can streamline our customers’ workflows and reduce their costs. This makes us relevant in a market characterized

SALES RECORD FOR CHROMTOGRAPHY PRODUCTS In 2024, we reached our highest sales of chromatography products ever with net sales of SEK 14.5 million, of which SEK 6.7 million in the fourth quarter. Sales of our silica media NLAB Saga® were able to start during the summer after we finalized and approved significantly larger volumes of silica than before from our large-scale production facility. Production of silica has continued to stabilize during the year, which has